• 6767 Bertner Ave, Mitchell Basic Science Research Building

    77030 Houston

    United States

  • 8919 Citations
  • 44 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Filip Janku is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer

Pairawan, S., Hess, K. R., Janku, F., Sanchez, N. S., Shaw, K. R. M., Eng, C., Damodaran, S., Javle, M., Kaseb, A. O., Hong, D. S., Subbiah, V., Fu, S., Fogelman, D. R., Raymond, V. M., Lanman, R. B. & Meric-Bernstam, F., Apr 15 2020, In : Clinical Cancer Research. 26, 8, p. 1924-1931 8 p.

Research output: Contribution to journalArticle

  • Open Access
  • Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

    Goyal, G., Heaney, M. L., Collin, M., Cohen-Aubart, F., Vaglio, A., Durham, B. H., Hershkovitz-Rokah, O., Girschikofsky, M., Jacobsen, E. D., Toyama, K., Goodman, A. M., Hendrie, P., Cao, X. X., Estrada-Veras, J. I., Shpilberg, O., Abdo, A., Kurokawa, M., Dagna, L., McClain, K. L., Mazor, R. D. & 5 others, Picarsic, J., Janku, F., Go, R. S., Haroche, J. & Diamond, E. L., May 28 2020, In : Blood. 135, 22, p. 1929-1945 17 p.

    Research output: Contribution to journalArticle

    Open Access
  • First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors

    Falchook, G. S., Kurzrock, R., Amin, H. M., Xiong, W., Fu, S., Piha-Paul, S. A., Janku, F., Eskandari, G., Catenacci, D. V., Klevesath, M., Bruns, R., Stammberger, U., Johne, A., Bladt, F., Friese-Hamim, M., Girard, P., Bawab, S. E. & Hong, D. S., Mar 15 2020, In : Clinical Cancer Research. 26, 6, p. 1237-1246 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 2 Scopus citations

    Phase 2 study of pembrolizumab in patients with advanced rare cancers

    Naing, A., Meric-Bernstam, F., Stephen, B., Karp, D. D., Hajjar, J., Rodon Ahnert, J., Piha-Paul, S. A., Colen, R. R., Jimenez, C., Raghav, K. P., Ferrarotto, R., Tu, S. M., Campbell, M., Wang, L., Sabir, S. H., Tapia, C., Bernatchez, C., Frumovitz, M., Tannir, N., Ravi, V. & 20 others, Khan, S., Painter, J. M., Abonofal, A., Gong, J., Alshawa, A., McQuinn, L. M., Xu, M., Ahmed, S., Subbiah, V., Hong, D. S., Pant, S., Yap, T. A., Tsimberidou, A. M., Dumbrava, E. E. I., Janku, F., Fu, S., Simon, R. M., Hess, K. R., Varadhachary, G. R. & Amir Habra, M., Mar 1 2020, In : Journal for immunotherapy of cancer. 8, 1

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations